Is Fluralaner (Bravecto) safe for dogs and cats?
Moderate risk for petsFluralaner presents a moderate risk to dogs, driven by the class-wide FDA-required neurological adverse event warning for isoxazoline ectoparasiticides. In the vast majority of dogs, Bravecto (fluralaner) is well-tolerated and provides excellent 12-week flea and tick protection from a single dose — a major practical advantage for compliance. However, FDA pharmacovigilance data identified a subset of dogs developing neurological adverse events (muscle tremors, ataxia, seizures) during or after isoxazoline treatment, including some dogs without prior history of neurological disease. Dogs with pre-existing epilepsy, known seizure disorders, or neurological conditions are at higher risk and should use isoxazolines only under veterinary guidance with informed owner consent. The long half-life (~12–15 days; effects persist for weeks after a single dose) means that if neurological adverse events develop, the drug cannot be rapidly eliminated. Veterinary monitoring for the first 24–48 hours after the first dose is advisable in high-risk dogs.
What is fluralaner (bravecto)?
The IUPAC name is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide.
Also known as: 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide, Fluralaner, Bravecto, AH252723.
- IUPAC name
- 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide
- CAS number
- 864731-61-3
- Molecular formula
- C22H17Cl2F6N3O3
- Molecular weight
- 556.3 g/mol
- SMILES
- CC1=C(C=CC(=C1)C2=NOC(C2)(C3=CC(=CC(=C3)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F
- PubChem CID
- 25144319
Risk for dogs
Moderate riskFluralaner presents a moderate risk to dogs, driven by the class-wide FDA-required neurological adverse event warning for isoxazoline ectoparasiticides. In the vast majority of dogs, Bravecto (fluralaner) is well-tolerated and provides excellent 12-week flea and tick protection from a single dose — a major practical advantage for compliance. However, FDA pharmacovigilance data identified a subset of dogs developing neurological adverse events (muscle tremors, ataxia, seizures) during or after isoxazoline treatment, including some dogs without prior history of neurological disease. Dogs with pre-existing epilepsy, known seizure disorders, or neurological conditions are at higher risk and should use isoxazolines only under veterinary guidance with informed owner consent. The long half-life (~12–15 days; effects persist for weeks after a single dose) means that if neurological adverse events develop, the drug cannot be rapidly eliminated. Veterinary monitoring for the first 24–48 hours after the first dose is advisable in high-risk dogs.
Regulatory consensus
1 regulatory bodyhas classified Fluralaner (Bravecto).
| Agency | Year | Classification | Notes |
|---|---|---|---|
| IARC | 2022 | Not evaluated by IARC — fluralaner (Bravecto; MSD Animal Health/Merck Animal Health) is an FDA/CVM-approved isoxazoline ectoparasiticide for dogs and cats providing 12-week (dogs) or 8–12-week (cats) protection against fleas and ticks; FDA label carries a neurological adverse event warning (boxed warning or paragraph caution); no carcinogenicity classification |
Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.
Where pets encounter fluralaner (bravecto)
- Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
- Occupational Environments — Factories, Warehouses, Transportation vehicles
Safer alternatives
Lower-risk approaches that achieve a similar outcome to Fluralaner (Bravecto):
-
Alternative drug class; Non-pharmacological therapy; Lowest effective dose
Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.Relative cost: 1.2-2×
Frequently asked questions
Is fluralaner (bravecto) safe for pets?
Fluralaner presents a moderate risk to dogs, driven by the class-wide FDA-required neurological adverse event warning for isoxazoline ectoparasiticides. In the vast majority of dogs, Bravecto (fluralaner) is well-tolerated and provides excellent 12-week flea and tick protection from a single dose — a major practical advantage for compliance. However, FDA pharmacovigilance data identified a subset of dogs developing neurological adverse events (muscle tremors, ataxia, seizures) during or after isoxazoline treatment, including some dogs without prior history of neurological disease. Dogs with pre-existing epilepsy, known seizure disorders, or neurological conditions are at higher risk and should use isoxazolines only under veterinary guidance with informed owner consent. The long half-life (~12–15 days; effects persist for weeks after a single dose) means that if neurological adverse events develop, the drug cannot be rapidly eliminated. Veterinary monitoring for the first 24–48 hours after the first dose is advisable in high-risk dogs.
What products contain fluralaner (bravecto)?
Fluralaner (Bravecto) appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).
See Fluralaner (Bravecto) in the pets app
Look up products containing fluralaner (bravecto), compare to alternatives, and explore the full data record.
Open in pets View raw API dataSources (1)
- Fluralaner Bravecto MSD Animal Health FDA CVM; Isoxazoline GABA Chloride Channel Antagonist; 12-Week Duration Single Dose; FDA Neurological Adverse Event Warning 2018 2022 Tremors Ataxia Seizures; GABA-A Invertebrate Selectivity; Long Half-Life 12-15 Days Lipophilic Adipose; Bravecto Chewable Spot-On; Pharmacovigilance Post-Marketing; Aquatic Invertebrate Daphnia Ecotoxicity; IARC Not Evaluated (2022) — regulatory
Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →